Branded pharma worries, generics makers cheer as trade pact hits snag in Congress
17 June 2015
The Trans-Pacific Partnership took it on the chin Friday when the U.S. House voted against a key assistance program for workers displaced by global trade. That move throws a wrench into U.S. efforts to pass the controversial trade agreement, which pharma companies have lobbied hard to shape.
MSF wants Indian PM to stand up to Big Pharma peer pressure
17 June 2015
Western drugmakers have long struggled with India's populist attitude toward patents, and hoped there would be some light at the end of the tunnel with the latest spate of trade negotiations over generic drugs in the country. But Doctors Without Borders (MSF), a vocal critic of Big Pharma's patent tactics, is none too pleased with the proposed trade changes.
Pharma M&A and Financial Trends: The Frenzy and Risks Escalate
17 June 2015
Every day the newspapers are filled with stories about the pharma industry. Many are very positive, with reports of breakthroughs and novel approaches to solving difficult health issues, the commitment of the industry to attack some of the most difficult diseases and break through a myriad of structural roadblocks and escalating development costs. Others are more critical with complaints about drug pricing, the seemingly endless stream of take-overs, and the rush towards orphan drugs.
Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA
16 June 2015
Clearside Biomedical, Inc., a biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced a favorable End-of-Phase 2 review with the U.S. Food and Drug Administration (FDA) on its lead drug triamcinolone acetonide (TA) administered via injection into the suprachoroidal space (SCS) for the treatment of macular edema associated with non-infectious uveitis. Agreement was reached with the FDA for the overall development plan with a single pivotal Phase 3 clinical trial, and the company is finalizing plans to initiate this global study.
Tobira Finishes Patient Enrollment for NASH Study
16 June 2015
Tobira Therapeutics, Inc. has finished recruiting patients for its phase 2b CENTAURstudy, which was designed to evaluate a therapy called cenicriviroc (CVC) in patients who suffer from non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company, which is focused on developing and commercializing therapeutic options to treat liver and inflammatory conditions, announced enrollment completion in a press release.
Coda Therapeutics $3.43 million Fundraising. David Pool Published Jun 12 SEC Filing
16 June 2015
Coda Therapeutics Inc, Corporation just submitted form D announcing $3.43 million debt financing. This is a new filing. Coda Therapeutics was able to finance itself with $1.21 million so far. That is 35.16% of the financing offer. The total private financing amount was $3.43 million. The form was filled on 2015-06-12. The reason for the financing was: Total Offering Amount includes estimated amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer’s preferred stock (assuming no net issue exercise, where applicable).
New System to Detect Patient's Antibiotic Resistance to Take Just 30 Minutes
16 June 2015
A new device being developed by medical experts will transform the time it takes to detect antibiotic resistance in patients from several days to just half an hour.
VBlockbuster 2.0: Eight Ways to Follow that Leader
16 June 2015
Over the past decade, many industry journalists, analysts, and consultants presumed that specialty markets, pricing pressures, and pharmacogenetic testing would kill off billion-dollar products. However—to paraphrase Mark Twain—reports of the death of the blockbuster have been widely exaggerated.
New Study: Policy Environment Has a Significant Impact on Biopharmaceutical Investment
16 June 2015
Economies’ policy trajectories have a significant impact on biopharmaceutical investment decisions, perhaps more than costs and market size, according to local executives. A new study from Pugatch Consilium consultancy finds that economies with policy environments that support investment and innovation rank as the most attractive for biopharmaceutical investment in the eyes of top level executives operating on the ground.
Biotech payrolls boom along with sales, while Big Pharma jobs keep disappearing
16 June 2015
Biotech is booming, there's no escaping that fact. And once again, an employment report shows that the biotech boom extends to job growth that beats pharma. Once again, biotech payrolls are burgeoning as pharma's falter.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024